CN117327078A - 杂环化合物、包含其的药物组合物及其制备方法和用途 - Google Patents
杂环化合物、包含其的药物组合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN117327078A CN117327078A CN202311264080.7A CN202311264080A CN117327078A CN 117327078 A CN117327078 A CN 117327078A CN 202311264080 A CN202311264080 A CN 202311264080A CN 117327078 A CN117327078 A CN 117327078A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- group
- cycloalkyl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019101245846 | 2019-02-19 | ||
| CN201910124584 | 2019-02-19 | ||
| CN201910437878 | 2019-05-24 | ||
| CN2019104378784 | 2019-05-24 | ||
| CN201910932095 | 2019-09-29 | ||
| CN2019109320953 | 2019-09-29 | ||
| PCT/CN2020/074696 WO2020168939A1 (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CN202080009954.2A CN113316578B (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080009954.2A Division CN113316578B (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117327078A true CN117327078A (zh) | 2024-01-02 |
Family
ID=72143544
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311264080.7A Pending CN117327078A (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CN202311221283.8A Active CN117263945B (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CN202080009954.2A Active CN113316578B (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311221283.8A Active CN117263945B (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
| CN202080009954.2A Active CN113316578B (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220144847A1 (enExample) |
| EP (1) | EP3929198A4 (enExample) |
| JP (2) | JP7615056B2 (enExample) |
| KR (1) | KR102977603B1 (enExample) |
| CN (3) | CN117327078A (enExample) |
| AU (1) | AU2020226422C1 (enExample) |
| BR (1) | BR112021016299A2 (enExample) |
| CA (1) | CA3130245A1 (enExample) |
| CL (1) | CL2021002205A1 (enExample) |
| CO (1) | CO2021011023A2 (enExample) |
| IL (1) | IL285378B2 (enExample) |
| MX (1) | MX2021009971A (enExample) |
| PH (1) | PH12021552004A1 (enExample) |
| SA (1) | SA521430084B1 (enExample) |
| SG (1) | SG11202107848TA (enExample) |
| WO (1) | WO2020168939A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7688690B2 (ja) * | 2020-07-28 | 2025-06-04 | スーチュアン・コールン－バイオテック・バイオファーマシューティカル・カンパニー・リミテッド | ピリミジン系化合物の塩、結晶形およびその調製方法 |
| WO2022199503A1 (zh) | 2021-03-24 | 2022-09-29 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与激酶耐药突变相关的疾病的用途和方法 |
| CN114235976B (zh) * | 2021-11-09 | 2023-11-03 | 暨南大学 | 一种含氮杂环有机化合物中间产物的合成和分析方法 |
| CN120897743A (zh) | 2023-05-19 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与ret基因改变相关疾病的用途和方法 |
| WO2025256440A1 (zh) * | 2024-06-14 | 2025-12-18 | 四川科伦博泰生物医药股份有限公司 | 含杂环化合物富马酸盐的制备方法 |
| WO2026017002A1 (zh) * | 2024-07-16 | 2026-01-22 | 四川科伦博泰生物医药股份有限公司 | 以杂环化合物为活性成分的药物组合物、其制备方法及用途 |
| GB202410599D0 (en) * | 2024-07-19 | 2024-09-04 | Ellipses Pharma Ltd | Therapeutics useful synergistic combinations |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101166734A (zh) * | 2005-02-28 | 2008-04-23 | 日本烟草产业株式会社 | 具有Syk抑制活性的新型的氨基吡啶化合物 |
| WO2012154518A1 (en) * | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
| CN103298788A (zh) * | 2010-10-28 | 2013-09-11 | 日本新药株式会社 | 吡啶衍生物及医药 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0607062A2 (pt) * | 2005-02-28 | 2009-08-04 | Japan Tobacco Inc | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos |
| WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US20080234267A1 (en) * | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| JP2010208945A (ja) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| CN102812022B (zh) * | 2010-01-12 | 2016-02-03 | Ab科学有限公司 | 噻唑和噁唑激酶抑制剂 |
| JP2013107824A (ja) * | 2010-03-17 | 2013-06-06 | Dainippon Sumitomo Pharma Co Ltd | 新規単環ピリミジン誘導体 |
| US10202365B2 (en) * | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| RS65069B1 (sr) | 2015-11-02 | 2024-02-29 | Blueprint Medicines Corp | Inhibitori ret-a |
| TWI704148B (zh) * | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JP6888101B2 (ja) * | 2017-01-18 | 2021-06-16 | アレイ バイオファーマ インコーポレイテッド | ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物 |
-
2020
- 2020-02-11 JP JP2021571055A patent/JP7615056B2/ja active Active
- 2020-02-11 MX MX2021009971A patent/MX2021009971A/es unknown
- 2020-02-11 CN CN202311264080.7A patent/CN117327078A/zh active Pending
- 2020-02-11 WO PCT/CN2020/074696 patent/WO2020168939A1/zh not_active Ceased
- 2020-02-11 SG SG11202107848TA patent/SG11202107848TA/en unknown
- 2020-02-11 BR BR112021016299-2A patent/BR112021016299A2/pt unknown
- 2020-02-11 EP EP20760123.8A patent/EP3929198A4/en active Pending
- 2020-02-11 CN CN202311221283.8A patent/CN117263945B/zh active Active
- 2020-02-11 CN CN202080009954.2A patent/CN113316578B/zh active Active
- 2020-02-11 PH PH1/2021/552004A patent/PH12021552004A1/en unknown
- 2020-02-11 IL IL285378A patent/IL285378B2/en unknown
- 2020-02-11 AU AU2020226422A patent/AU2020226422C1/en active Active
- 2020-02-11 CA CA3130245A patent/CA3130245A1/en active Pending
- 2020-02-11 US US17/431,930 patent/US20220144847A1/en active Pending
- 2020-02-11 KR KR1020217022806A patent/KR102977603B1/ko active Active
-
2021
- 2021-08-17 SA SA521430084A patent/SA521430084B1/ar unknown
- 2021-08-18 CL CL2021002205A patent/CL2021002205A1/es unknown
- 2021-08-20 CO CONC2021/0011023A patent/CO2021011023A2/es unknown
-
2024
- 2024-12-27 JP JP2024231551A patent/JP7821259B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101166734A (zh) * | 2005-02-28 | 2008-04-23 | 日本烟草产业株式会社 | 具有Syk抑制活性的新型的氨基吡啶化合物 |
| CN103298788A (zh) * | 2010-10-28 | 2013-09-11 | 日本新药株式会社 | 吡啶衍生物及医药 |
| WO2012154518A1 (en) * | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
Non-Patent Citations (1)
| Title |
|---|
| LI, BING-KE，等: "In silico prediction of spleen tyrosine kinase inhibitors using machine learning approaches and an optimized molecular descriptor subset generated by recursive feature elimination method", 《COMPUTERS IN BIOLOGY AND MEDICINE 》, vol. 43, no. 4, 1 May 2013 (2013-05-01), pages 395 - 404, XP055143456, DOI: 10.1016/j.compbiomed.2013.01.015 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020226422A1 (en) | 2021-09-09 |
| IL285378B1 (en) | 2025-07-01 |
| PH12021552004A1 (en) | 2022-09-05 |
| NZ778907A (en) | 2025-05-30 |
| CN113316578A (zh) | 2021-08-27 |
| WO2020168939A1 (zh) | 2020-08-27 |
| CO2021011023A2 (es) | 2021-09-09 |
| AU2020226422C1 (en) | 2026-04-02 |
| JP7615056B2 (ja) | 2025-01-16 |
| JP7821259B2 (ja) | 2026-02-26 |
| KR20210131314A (ko) | 2021-11-02 |
| US20220144847A1 (en) | 2022-05-12 |
| IL285378A (en) | 2021-09-30 |
| JP2025060928A (ja) | 2025-04-10 |
| SG11202107848TA (en) | 2021-08-30 |
| SA521430084B1 (ar) | 2025-05-01 |
| AU2020226422B2 (en) | 2025-07-31 |
| CL2021002205A1 (es) | 2022-04-22 |
| EP3929198A1 (en) | 2021-12-29 |
| BR112021016299A2 (pt) | 2021-10-13 |
| CN113316578B (zh) | 2023-10-31 |
| JP2022521859A (ja) | 2022-04-12 |
| CN117263945A (zh) | 2023-12-22 |
| CN117263945B (zh) | 2026-08-11 |
| IL285378B2 (en) | 2025-11-01 |
| MX2021009971A (es) | 2021-10-13 |
| KR102977603B1 (ko) | 2026-06-12 |
| CA3130245A1 (en) | 2020-08-27 |
| EP3929198A4 (en) | 2022-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113316578B (zh) | 杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| JP7511294B2 (ja) | Ｆｇｆｒ阻害剤化合物及びその使用 | |
| JP6726677B2 (ja) | 抗がん剤としての置換２−ｈ−ピラゾール誘導体 | |
| JP2023554506A (ja) | Ｆｇｆｒ阻害剤化合物及びその使用 | |
| KR20230026288A (ko) | Sos1 억제제 및 이의 용도 | |
| CN113330009B (zh) | 氮杂环化合物、其制备方法及用途 | |
| CN111484479B (zh) | 氮杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| CN112574201B (zh) | 芳基胺类化合物、包含其的药物组合物及其制备方法和用途 | |
| CN113993861B (zh) | 吡唑基-氨基-嘧啶基衍生物的苯醚和苯胺及其组合物和方法 | |
| WO2020186220A1 (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| JP7343622B2 (ja) | Ｆｇｆｒとｖｅｇｆｒ二重阻害剤としての縮合環系化合物 | |
| CN116057045A (zh) | 成纤维细胞生长因子受体激酶抑制剂 | |
| JP2024511389A (ja) | キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 | |
| CN114621186A (zh) | 作为ras信号通路调控剂的杂环化合物 | |
| RU2828045C2 (ru) | Гетероциклическое соединение, фармацевтическая композиция, содержащая его, способ его получения и его применение | |
| HK40051009A (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| CN115043844B (zh) | Trk激酶抑制剂化合物及其用途 | |
| HK40051009B (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| JP2025526717A (ja) | ＴＧＦ－β阻害剤化合物及びその使用 | |
| CN116761801A (zh) | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| HK40085563A (en) | Inhibitors of fibroblast growth factor receptor kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |